lansoprazole has been researched along with ranitidine in 126 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 58 (46.03) | 18.2507 |
| 2000's | 49 (38.89) | 29.6817 |
| 2010's | 19 (15.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barth, H; Dammann, HG; Hengels, KJ; Kleinert, R; Londong, W; Müller, P; Rohde, H; Simon, B | 1 |
| Maki, Y; Nagaya, H; Satoh, H | 1 |
| Atkinson, BF; Brightman, SA; Jhala, NC; McFarland, MM; Morale, B; Rubin, W | 1 |
| Fujio, Y; Hirohata, S; Honsako, Y; Kashio, Y; Konishi, M; Kumada, H; Miura, J; Miyamoto, M; Tamada, F; Yamamoto, T | 1 |
| Bardhan, KD; Brocklebank, D; Hawkey, CJ; Long, RG; Morgan, AG; Moules, IK; Wormsley, KG | 1 |
| Bazin, B; Bigard, MA; Colin, R; Duhamel, C; Legoux, JL; Michel, P; Person, B; Raoul, JL; Sallerin, V | 1 |
| Avner, D; Greski-Rose, PA; Jennings, DE; Jhala, N; Robinson, M; Sahba, B | 1 |
| Ahlberg, J; Bardhan, KD; Hislop, WS; Lindholmer, C; Long, RG; Morgan, AG; Sjostedt, S; Smith, PM; Stig, R; Wormsley, KG | 1 |
| Goff, J; Greski-Rose, P; Jennings, D; Lanza, F; Scowcroft, C | 1 |
| Feldman, M; Fisher, RS; Greski-Rose, PA; Harford, WV; Jennings, DE; Murray, SB; Sampliner, RE | 1 |
| Bigard, MA; Bommelaer, G; Colin, R; Dupas, JL; Lemaire, M; Michel, P; Rambaud, JC; Verwaerd, JC | 1 |
| Bardhan, KD; Christian, J; Cochran, KM; Hawkey, CJ; Long, RG; Moules, IK; Wormsley, KG | 1 |
| Arakawa, T; Fukuda, T; Higuchi, K; Kimura, S; Kobayashi, K; Uchida, T | 1 |
| Berstad, A; Hatlebakk, JG | 2 |
| Arnold, R; Brunner, G; Fuchs, W; Hennig, U | 1 |
| Agostini, H; Lemaire, M; Poynard, T | 1 |
| Maekawa, N; Mikawa, K; Nishina, K; Obara, H; Shiga, M; Takao, Y | 2 |
| Christian, J; Foster, CS; Garrett, AD; Gough, AL; Langworthy, CH; Swarbrick, ET | 1 |
| Cooper, BT; Fosters, CS; Garrett, AD; Gough, AL; Langworthy, CH; Long, RG | 1 |
| Asano, S; Inatomi, N; Murakami, I; Nagaya, H; Satoh, H; Yukishige, K | 1 |
| Asano, S; Inada, I; Inatomi, N; Murakami, I; Satoh, H | 1 |
| Campbell, DR; Castell, D; Fleischmann, R; Kogut, DG; Lehman, GA; McFarland, M; Richter, J; Robinson, M; Sabesin, S; Sontag, SJ | 1 |
| Chey, WD; DelValle, J; Nostrant, TT; Scheiman, JM; Woods, M | 1 |
| Bargiggia, S; Bianchi Porro, G; Lazzaroni, M | 1 |
| Arnestad, JS; Kleveland, PM; Waldum, HL | 1 |
| Ido, K; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Takimoto, T; Taniguchi, Y; Yamamoto, H; Yoshida, Y | 1 |
| Baxter, G; Jones, RH | 1 |
| Fuchs, W; Müller, P; Simon, B | 1 |
| Isolauri, J; Nevalainen, J; Viljakka, M | 1 |
| Hirakawa, T | 1 |
| Ammon, S; Klotz, U; Treiber, G | 1 |
| Levy, N; Neeman, I; Stermer, E; Tabak, M | 1 |
| Harris, RA; Kuppermann, M; Richter, JE | 1 |
| Dixon, JS; Pipkin, GA; Williamson, R; Wood, JR | 1 |
| Fennerty, MB | 1 |
| Dattilo, M; Russo, A | 1 |
| King, VJ | 1 |
| Hetzel, D | 1 |
| Lambert, JR; Treiber, G | 1 |
| Alarcón, T; Domingo, D; López-Brea, M; Martínez, MJ; Sánchez, I; Sanz, JC | 1 |
| Kiel, G; Meining, A; Stolte, M | 1 |
| De Fanis, C; Di Virgilio, M; Pantaleone, U; Pizzicanella, G; Russo, L; Sciampa, G; Silla, M; Spadaccini, A | 1 |
| Howden, CW; Hunt, RH | 1 |
| Freedman, MD | 1 |
| Collier, DS; Olsen, KM; Peddicord, TE | 1 |
| Bertaccini, G; Coppelli, G; Coruzzi, G; Frati, P | 1 |
| Kihira, K; Kimura, K; Kumakura, Y; Sato, K; Sugano, K; Yoshida, Y | 1 |
| Kanayama, S | 1 |
| Freston, JW; Haber, M; Heller, CA; Jennings, D; Rose, PA | 1 |
| Mulder, PG; Samsom, M; Smout, AJ; van Herwaarden, MA; van Nispen, CH | 1 |
| Bardhan, KD; Crouch, SL; Crowe, J; Keeling, PN; Thompson, RP; Trewby, PN; Weir, D | 1 |
| Cross, R; Grimley, CE; Illing, RC; Lismore, JR; Loft, DE; Nwokolo, CU; O'sullivan, M; Penny, A; Shebani, M | 1 |
| Itoh, M; Joh, T; Kurokawa, T; Sasakii, M; Seno, K; Tsuchida, K; Yokoyama, Y | 1 |
| Bravo, LE; Campo, C; Correa, P; Mera, R; Realpe, JL | 1 |
| Arakawa, T; Ohara, T | 1 |
| Dave, B; Rubin, W | 1 |
| Jansen, JB; Van Oene, JC | 1 |
| Fujita, N; Kassai, K; Kondo, M; Naito, Y; Tanaka, Y; Yoshida, N; Yoshikawa, T | 1 |
| Agrawal, NM; Campbell, DR; Haber, MM; Huang, B; Lukasik, NL; Safdi, MA | 1 |
| Ammon, S; Kees, F; Klotz, U; Treiber, G | 1 |
| Campbell, DR; Fludas, C; Huang, B; Kahrilas, PJ; Richter, JE | 1 |
| Buzás György, M; Illyés, G; Székely, E; Széles, I | 1 |
| Habu, Y; Inokuchi, H; Kawai, K; Kiyota, K; Oyasu, K; Sumitomo, Y; Wakamatsu, T | 1 |
| Lanas, AI | 1 |
| Castell, DO; Katz, PO; Katzka, DA; Ramakrishnan, A; Srinivasan, R; Vela, MF | 1 |
| Anic, T; Aralica, G; Bilic, I; Buljat, G; Ivankovic, D; Mikus, D; Mise, S; Perovic, D; Petek, M; Prkacin, I; Rotkvic, I; Rucman, R; Seiwerth, S; Separovic, J; Sikiric, P; Stancic-Rokotov, D; Zoricic, I | 1 |
| Bardou, M | 1 |
| Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V | 1 |
| McGuigan, JE | 1 |
| Freston, JW; Henning, JM; Howden, CW; Huang, B; Lukasik, N | 1 |
| Dixon, CA; Hopkins, RJ; Meyer, JM; Siepman, NY; Silliman, NP; Sugg, JE | 1 |
| Caro, JJ; Salas, M; Ward, A | 1 |
| Cimmino, A; Melton, ST | 1 |
| Colwell, HH; Henning, JM; Mathias, SD; Miller, DP; Ofman, JJ; Pasta, DJ | 1 |
| Ammon, S; Klotz, U; Treiber, G; van Doorn, LJ; Walker, S; Wittig, J | 1 |
| Beck, IT | 1 |
| Andriulli, A; Clemente, R; Festa, V; Merla, A; Perri, F; Quitadamo, M | 1 |
| Adachi, K; Kinoshita, Y | 1 |
| Astudillo, L; Rodriguez, JA; Schmeda-Hirschmann, G | 1 |
| Hiraishi, H; Ota, S; Terano, A | 1 |
| Campbell, DR; Collis, C; Goldstein, JL; Haber, MM; Huang, B; Lukasik, N; Sheldon, E | 1 |
| Babkova, IV; Cherniakevich, SA; Mikhalev, AI | 1 |
| Abraham, D; Saltoun, CA | 1 |
| Kamolz, T; Pointner, R; Velanovich, V | 1 |
| Abu Farsakh, N | 1 |
| Johnston, G; Lee, C; Stolle, J; Tolia, V | 1 |
| Färkkilä, MA; Heikkinen, MT; Koivisto, TT; Koskenpato, JP; Rautelin, HI; Voutilainen, ME | 1 |
| Adem, A; Adeyemi, EO; Bastaki, SA; Chandranath, IS; Fahim, M; Hasan, MY | 1 |
| Brodsky, L; Ulualp, S | 1 |
| Habu, Y; Hayakumo, T; Hayashi, K; Kawai, K; Kusuda, T; Maeda, K; Shio, S; Watanabe, Y; Yamazaki, M; Yoshino, T | 1 |
| Bozkurt, B; Demirkan, K; Kalyoncu, AF; Karakaya, G | 1 |
| Apikoglu-Rabus, S; Besisik, F; Dulger, G; Izzettin, FV; Sancar, M; Tozun, N | 1 |
| Esplugues, JV; Martí-Cabrera, M; Ponce, J | 1 |
| Fukui, Y; Habu, Y; Hisatsune, H; Kawai, K; Maruno, T | 1 |
| Serebrova, SIu | 1 |
| Cadirci, E; Dengiz, GO; Halici, Z; Odabasoglu, F; Suleyman, H | 1 |
| Duffill, M; Hill, S; Lamont, D; Rademaker, M; Yung, A | 1 |
| Atkinson, S; Freston, JW; Haber, MM; Hunt, B; Kovacs, TO; Peura, DA | 2 |
| Baer, VL; Barney, CK; Christensen, RD; Cook, M; Lambert, DK; Scoffield, SH | 1 |
| Atkinson, S; Freston, JW; Haber, MM; Hisada, M; Hunt, B; Kovacs, TO; Peura, DA | 1 |
| Hunt, R; Sachs, G; Shin, JM | 1 |
| Kato, M; Nema, H | 1 |
| Adem, A; Bastaki, SM; Chandranath, SI; D'Souza, A; Singh, J | 1 |
| Kasiwong, S; Mahattanadul, S; Nima, S; Phdoongsombut, N; Ratanasuwon, P; Ridtitid, W | 1 |
| Garza, JM; Kaul, A; Nylund, CM | 1 |
| Eberlein, B; Gebhardt, E; Gilbertz, KP; Placzek, M; Przybilla, B | 1 |
| Arslan, MS; Aydogdu, B; Okur, MH; Otcu, S; Uygun, I | 1 |
| Ateş, Y; Avşar, E; Aytuğ, N; Bektaş, A; Bölükbaş, C; Dinçer, D; Ellidokuz, E; Erzin, Y; Güliter, S; Kaymakoğlu, S; Kocakaya, O; Onuk, MD; Poturoğlu, S; Taşan, G; Tiftikçi, A; Türkay, C; Yıldırım, B; Yılmaz, U | 1 |
| Niv, Y | 1 |
20 review(s) available for lansoprazole and ranitidine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Lansoprazole in the treatment of reflux oesophagitis: a survey of clinical studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Ranitidine | 1993 |
Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Ranitidine; Time Factors; Wound Healing | 1995 |
Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Benzimidazoles; Cimetidine; Cisapride; Domperidone; Famotidine; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Metoclopramide; Nizatidine; Omeprazole; Pantoprazole; Piperidines; Proton Pump Inhibitors; Ranitidine; Sucralfate; Sulfoxides | 1996 |
[Diagnosis and treatment of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Bacteriological Techniques; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Polymerase Chain Reaction; Ranitidine | 1997 |
Clarithromycin dual therapy regimens for eradication of Helicobacter pylori: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Ranitidine | 1997 |
Acid pump inhibitors. The treatment of gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cisapride; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Pantoprazole; Piperidines; Ranitidine; Sulfoxides | 1998 |
The impact of Helicobacter pylori eradication on peptic ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Odds Ratio; Omeprazole; Pantoprazole; Peptic Ulcer; Ranitidine; Stomach Ulcer; Sulfoxides; Treatment Outcome; Wound Healing | 1998 |
[Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Famotidine; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Ranitidine | 1999 |
Safety profile of Lansoprazole: the US clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Esophageal Diseases; Gastric Acid; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Ranitidine; United States | 1999 |
[Cost-effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine-2-receptor antagonist].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Cost-Benefit Analysis; Enzyme Inhibitors; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Ranitidine | 2000 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child; Child, Preschool; Duodenal Ulcer; Enzyme Inhibitors; Esophagitis, Peptic; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Infant; Infant, Newborn; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Ranitidine; Stomach Ulcer; Sulfoxides | 2001 |
Helicobacter pylori and early duodenal ulcer status post-treatment: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Duodenal Ulcer; Follow-Up Studies; Helicobacter Infections; Humans; Lansoprazole; Odds Ratio; Omeprazole; Ranitidine; Research Design; Retrospective Studies; United States; United States Food and Drug Administration | 2001 |
Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Rabeprazole; Randomized Controlled Trials as Topic; Ranitidine; Sulfoxides; Treatment Outcome | 2001 |
[Cause and prevention of nocturnal gastric acid breakthrough].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Circadian Rhythm; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Esophagitis, Peptic; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Ranitidine | 2002 |
[Treatment of NSAID-associated gastric ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Ranitidine; Stomach Ulcer | 2002 |
The impact of gastroesophageal reflux disease on quality of life.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Combined Modality Therapy; Cross-Over Studies; Double-Blind Method; Esophagitis; Fundoplication; Gastroesophageal Reflux; Humans; Lansoprazole; Laparoscopy; Omeprazole; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Ranitidine; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome | 2003 |
Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anaphylaxis; Anti-Ulcer Agents; Benzimidazoles; Famotidine; Female; Gastroesophageal Reflux; Gastrointestinal Diseases; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Ranitidine; Skin Tests | 2006 |
[Safety of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Age Factors; Aged; Animals; Anti-Ulcer Agents; Cimetidine; Enzyme Inhibitors; Famotidine; Female; Fetus; Histamine H2 Antagonists; Humans; Lactation; Lansoprazole; Meta-Analysis as Topic; Nizatidine; Omeprazole; Pantoprazole; Pregnancy; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Ranitidine; Safety; Time Factors | 2006 |
Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Clarithromycin; Doxycycline; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Metronidazole; Proton Pump Inhibitors; Ranitidine; Tetracycline | 2016 |
53 trial(s) available for lansoprazole and ranitidine
| Article | Year |
|---|---|
Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; Duodenal Ulcer; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Ranitidine | 1991 |
The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pyloric Antrum; Ranitidine | 1995 |
Quantitative analysis of the gastric ulcer healing process using video endoscopic pseudocolor imaging systems.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Epithelium; Female; Hemoglobins; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Ranitidine; Stomach Ulcer; Video Recording | 1995 |
Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Double-Blind Method; Esophagitis, Peptic; Follow-Up Studies; H(+)-K(+)-Exchanging ATPase; Headache; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Ranitidine; Treatment Outcome | 1995 |
[Lansoprazole versus ranitidine in the prevention of early recurrences of digestive hemorrhages from gastroduodenal ulcers. Randomized double-blind multicenter study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Gastrointestinal Hemorrhage; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Ranitidine; Recurrence; Stomach Ulcer; Time Factors | 1994 |
A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Alcohol Drinking; Anti-Ulcer Agents; Caffeine; Double-Blind Method; Drug Evaluation; Esophagitis, Peptic; Female; Gastroscopy; Humans; Lansoprazole; Longitudinal Studies; Male; Omeprazole; Proton Pump Inhibitors; Ranitidine; Smoking | 1995 |
Rapid healing of gastric ulcers with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Ranitidine; Safety; Stomach Ulcer | 1994 |
Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Duodenal Ulcer; Female; Gastric Mucosa; Gastrins; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Ranitidine | 1994 |
Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Double-Blind Method; Esophagitis, Peptic; Female; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Ranitidine; Time Factors | 1993 |
Short report: treatment of gastric ulcer with lansoprazole or ranitidine: a multicentre clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Ranitidine; Stomach Ulcer | 1994 |
Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Ranitidine; Time Factors | 1993 |
Lansoprazole in the treatment of reflux oesophagitis: a survey of clinical studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Ranitidine | 1993 |
An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Duodenal Ulcer; Enterochromaffin Cells; Esophagitis; Female; Follicle Stimulating Hormone; Gastric Mucosa; Gastrins; Humans; Lansoprazole; Luteinizing Hormone; Male; Omeprazole; Peptic Ulcer; Pyloric Antrum; Ranitidine; Stomach Ulcer; Testosterone | 1993 |
A comparison of lansoprazole, omeprazole, and ranitidine for reducing preoperative gastric secretion in adult patients undergoing elective surgery.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Gastric Juice; Histamine H2 Antagonists; Humans; Lansoprazole; Middle Aged; Omeprazole; Preoperative Care; Ranitidine; Secretory Rate | 1996 |
Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dilatation; Double-Blind Method; Drug Administration Schedule; Esophageal Stenosis; Humans; Lansoprazole; Omeprazole; Prospective Studies; Ranitidine; Recurrence; Treatment Outcome | 1996 |
Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Diarrhea; Double-Blind Method; Enzyme Inhibitors; Esophagitis, Peptic; Female; Gastritis; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Ranitidine | 1996 |
Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Double-Blind Method; Drug Resistance; Esophagitis, Peptic; Esophagoscopy; Fasting; Female; Follow-Up Studies; Gastrins; Heartburn; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Ranitidine; Safety; Sleep; Sleep Stages; Ulcer; Wound Healing | 1997 |
Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Costs and Cost Analysis; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Proton Pump Inhibitors; Ranitidine; Single-Blind Method; Time Factors | 1997 |
In single doses ranitidine effervescent is more effective than lansoprazole in decreasing gastric acidity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Capsules; Cross-Over Studies; Depression, Chemical; Gastric Acid; Gastric Acidity Determination; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Ranitidine; Tablets | 1997 |
Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Humans; Lansoprazole; Middle Aged; Omeprazole; Ranitidine; Treatment Outcome | 1997 |
[Studies on the protective effect of lansoprazole on human gastric mucosa against low-dose acetylsalicylic acid. An endoscopic controlled double-blind study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aspirin; Double-Blind Method; Duodenoscopy; Gastroscopy; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Platelet Aggregation Inhibitors; Ranitidine | 1997 |
Lifetime costs of surgical versus medical treatment of severe gastro-oesophageal reflux disease in Finland.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Distribution; Aged; Chronic Disease; Cost of Illness; Enzyme Inhibitors; Female; Finland; Follow-Up Studies; Fundoplication; Gastroesophageal Reflux; Health Care Costs; Humans; Lansoprazole; Life Expectancy; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Quality of Life; Ranitidine | 1997 |
Age-dependent eradication of Helicobacter pylori with dual therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Age Factors; Aged; Amoxicillin; Anti-Ulcer Agents; Area Under Curve; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastric Acid; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Metabolic Clearance Rate; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Ranitidine | 1997 |
Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Metronidazole; Omeprazole; Penicillins; Placebos; Proton Pump Inhibitors; Ranitidine; Tetracycline | 1998 |
Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bed Rest; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Duodenal Ulcer; Endoscopy, Digestive System; Female; Follow-Up Studies; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Ranitidine; Recurrence; Treatment Outcome | 1997 |
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pyloric Antrum; Ranitidine; Treatment Outcome | 1998 |
Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Ranitidine; Time Factors; Tinidazole | 1998 |
[Triple therapy regimens involving H2 blockaders for therapy of Helicobacter pylori infections].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Ranitidine; Treatment Outcome | 1999 |
The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Double-Blind Method; Female; Gastric Acid; Gastric Acidity Determination; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Ranitidine | 1999 |
Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Duodenal Ulcer; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Ranitidine; Recurrence | 1999 |
Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Ranitidine; Treatment Outcome | 1999 |
The therapeutic effect of proton pump inhibitors on Helicobacter pylori-positive gastric ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Famotidine; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Multivariate Analysis; Nizatidine; Omeprazole; Patient Dropouts; Proton Pump Inhibitors; Ranitidine; Stomach Ulcer; Treatment Outcome | 1999 |
Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cell Count; Enzyme Inhibitors; Female; Humans; Intercellular Adhesion Molecule-1; Lansoprazole; Lymphocyte Subsets; Male; Monocytes; Omeprazole; Proton Pump Inhibitors; Ranitidine; Receptors, Interleukin-2 | 1999 |
Inhibition of gastric secretion relieves diarrhea and postprandial urgency associated with irritable bowel syndrome or functional diarrhea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Chronic Disease; Colonic Diseases, Functional; Diarrhea; Eating; Famotidine; Gastric Acid; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Ranitidine | 1999 |
Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Endoscopy; Eructation; Esophagitis, Peptic; Female; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pain; Ranitidine; Time Factors | 1999 |
A comparison of rabeprazole, lansoprazole, and ranitidine for improving preoperative gastric fluid property in adults undergoing elective surgery.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Elective Surgical Procedures; Female; Gastric Juice; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pneumonia, Aspiration; Prospective Studies; Rabeprazole; Ranitidine | 2000 |
Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Ranitidine; Stomach Ulcer; Wound Healing | 2000 |
Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Aged, 80 and over; Antacids; Anti-Ulcer Agents; Diarrhea; Double-Blind Method; Drug Administration Schedule; Esophagoscopy; Female; Gastroesophageal Reflux; Heartburn; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Ranitidine; Risk Factors; Treatment Outcome | 2000 |
[Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Ranitidine; Treatment Outcome | 2000 |
Maximal acid reflux control for Barrett's oesophagus: feasible and effective.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Barrett Esophagus; Endoscopy, Digestive System; Epithelium; Esophagus; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Ranitidine | 2001 |
Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Female; Headache; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pruritus; Ranitidine; Recurrence; Taste Disorders; Tinidazole; Treatment Outcome | 2001 |
Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Family Practice; Gastroesophageal Reflux; Heartburn; Histamine H2 Antagonists; Humans; Lansoprazole; Middle Aged; Omeprazole; Proton Pump Inhibitors; Ranitidine; Time Factors | 2001 |
Health-Related quality-of-life and quality-days incrementally gained in symptomatic nonerosive GERD patients treated with lansoprazole or ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Omeprazole; Patient Satisfaction; Quality of Life; Ranitidine; Socioeconomic Factors; Surveys and Questionnaires | 2001 |
Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Ranitidine; Regression Analysis; Treatment Outcome | 2002 |
Amoxicillin/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Ranitidine; Tetracycline; Treatment Failure | 2002 |
Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies; Ranitidine; Time Factors; Wound Healing | 2002 |
First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Multivariate Analysis; Omeprazole; Ranitidine; Risk Factors | 2005 |
Pharmacoeconomic comparison of Helicobacter pylori eradication regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Infective Agents; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Melena; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Prospective Studies; Ranitidine; Taste Disorders; Time Factors; Treatment Outcome | 2006 |
Lansoprazole for long-term maintenance therapy of erosive esophagitis: double-blind comparison with ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Esophagitis; Female; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Quality of Life; Ranitidine; Secondary Prevention; Time Factors; Treatment Outcome; United States; Wound Healing; Young Adult | 2009 |
Long-term quality of life improvement in subjects with healed erosive esophagitis: treatment with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Ulcer Agents; Double-Blind Method; Esophagitis; Female; Humans; Lansoprazole; Male; Middle Aged; Quality of Life; Ranitidine; Surveys and Questionnaires; Treatment Outcome | 2010 |
Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Double-Blind Method; Esophagitis; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Ranitidine; Time Factors | 2010 |
Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Drug Therapy, Combination; Endoscopy; Famotidine; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Ranitidine; Treatment Outcome; Wound Healing | 2010 |
A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Endoscopy, Digestive System; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Ranitidine; Treatment Outcome; Young Adult | 2013 |
54 other study(ies) available for lansoprazole and ranitidine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphate; Animals; Bucladesine; Carbachol; Cycloheximide; Dogs; Female; Gastric Acid; Histamine Antagonists; Lansoprazole; Male; Omeprazole; Parietal Cells, Gastric; Puromycin; Ranitidine | 1990 |
Proton-pump inhibitor-refractory gastric ulcer and Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Ranitidine; Stomach Ulcer | 1993 |
[Effects of lansoprazole on indomethacin-induced gastric bleeding and mucosal lesions in rats].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Famotidine; Gastric Mucosa; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Indomethacin; Lansoprazole; Male; Omeprazole; Ranitidine; Rats; Rats, Sprague-Dawley | 1996 |
[Effects of intravenous lansoprazole on acute gastric mucosal lesions and acid secretion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Animals; Anti-Ulcer Agents; Famotidine; Gastric Acid; Gastric Mucosa; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Injections, Intravenous; Lansoprazole; Male; Omeprazole; Ranitidine; Rats; Rats, Sprague-Dawley; Stress, Physiological | 1996 |
Lansoprazole and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent mechanism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Carbon Dioxide; Carbon Radioisotopes; False Negative Reactions; Female; Forecasting; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Monitoring, Ambulatory; Omeprazole; Ranitidine; Stomach; Urea | 1997 |
Comparison of ranitidine and lansoprazole in short-term low-dose triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Ranitidine | 1997 |
Lanzoprazole and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent mechanism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Carbon Dioxide; Carbon Radioisotopes; False Negative Reactions; Helicobacter pylori; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Radiopharmaceuticals; Ranitidine; Urea | 1997 |
Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Case-Control Studies; Cost-Benefit Analysis; Decision Support Techniques; Delphi Technique; Drug Costs; Enzyme Inhibitors; Esophagitis, Peptic; Follow-Up Studies; Gastroenterology; Histamine H2 Antagonists; Humans; Lansoprazole; Medicare; Omeprazole; Probability; Proton Pump Inhibitors; Quality of Life; Randomized Controlled Trials as Topic; Ranitidine; Recurrence; Relative Value Scales; Sensitivity and Specificity; United States; Value of Life | 1997 |
PPIs vs H2RAs for erosive reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Cost-Benefit Analysis; Enzyme Inhibitors; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Lansoprazole; Markov Chains; Omeprazole; Ranitidine; Recurrence; Reproducibility of Results | 1998 |
In vitro activity of ebrotidine, ranitidine, omeprazole, lansoprazole, and bismuth citrate against clinical isolates of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzenesulfonates; Helicobacter pylori; Lansoprazole; Microbial Sensitivity Tests; Omeprazole; Organometallic Compounds; Ranitidine; Thiazoles | 1998 |
Treating Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Combinations; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Ranitidine | 1998 |
Stress ulcer prevention and histamine-2-receptor antagonists: leaps of faith or back to the drawing board?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Histamine H2 Antagonists; Humans; Intensive Care Units; Lansoprazole; Omeprazole; Peptic Ulcer; Ranitidine; Stress, Physiological | 1999 |
Effect of omeprazole, lansoprazole, and ranitidine on the DNA synthesis of mononuclear cells.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Critical Care; DNA; Histamine H2 Antagonists; Humans; Immunity, Cellular; Lansoprazole; Leukocytes, Mononuclear; Male; Omeprazole; Proton Pump Inhibitors; Radionuclide Imaging; Radiopharmaceuticals; Ranitidine; Stomach Ulcer; Thymidine; Tritium | 1999 |
Effects of different antisecretory drugs on gastric potential difference in the rat: comparison with sucralfate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Aspirin; Drug Interactions; Gastric Acid; Lansoprazole; Male; Nizatidine; Omeprazole; Proton Pump Inhibitors; Ranitidine; Rats; Rats, Wistar; Sucralfate | 1998 |
Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antigens, Bacterial; Bismuth; Breath Tests; Feces; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Organometallic Compounds; Ranitidine; Salicylates; Sensitivity and Specificity; Urea | 1999 |
A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion; Cell Adhesion Molecules; Cell Communication; Cell Culture Techniques; Endothelium; Enzyme Inhibitors; Famotidine; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Neutrophils; Omeprazole; Proton Pump Inhibitors; Ranitidine; Stomach Ulcer | 2000 |
Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Creatinine; Female; Helicobacter Infections; Helicobacter pylori; Humans; Kidney; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Ranitidine | 2000 |
Current approaches to reducing gastrointestinal toxicity of low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Misoprostol; Omeprazole; Peptic Ulcer; Ranitidine | 2001 |
Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Atropine; Benzimidazoles; Bromocriptine; Cimetidine; Disease Models, Animal; Domperidone; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; Indomethacin; Lansoprazole; Male; Mice; Mice, Inbred Strains; Misoprostol; Omeprazole; Pantoprazole; Peptide Fragments; Proteins; Ranitidine; Stomach Diseases; Sulfoxides | 2001 |
Treatment of gastroesophageal reflux disease: to step or not to step.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Gastroesophageal Reflux; Heartburn; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Ranitidine | 2001 |
What is the best pharmacologic approach to managing moderate to severe heartburn?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Double-Blind Method; Female; Heartburn; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Multicenter Studies as Topic; Omeprazole; Proton Pump Inhibitors; Ranitidine; Reproducibility of Results; Treatment Outcome | 2001 |
In support of "step-up therapy" for gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Omeprazole; Prospective Studies; Ranitidine; Treatment Outcome | 2002 |
Gastroprotective activity of oleanolic acid derivatives on experimentally induced gastric lesions in rats and mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Aspirin; Dose-Response Relationship, Drug; Ethanol; Hydrochloric Acid; Lansoprazole; Ligation; Male; Mice; Molecular Structure; Oleanolic Acid; Omeprazole; Phytotherapy; Pylorus; Ranitidine; Rats; Rats, Sprague-Dawley; Solanaceae; Stomach Ulcer; Toxicity Tests, Acute | 2002 |
[Results of pre- and postoperative treatment of complicated duodenal ulcers with proton pump inhibitors ].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Follow-Up Studies; Humans; Lansoprazole; Omeprazole; Peptic Ulcer Hemorrhage; Peptic Ulcer Perforation; Postoperative Care; Proton Pump Inhibitors; Ranitidine; Time Factors | 2002 |
Facial swelling and eosinophilia in a 44-year-old woman.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Angioedema; Cefuroxime; Cetirizine; Diagnosis, Differential; Drug Hypersensitivity; Edema; Eosinophilia; Face; Fatigue; Female; Humans; Hypereosinophilic Syndrome; Indoles; Lansoprazole; Methylprednisolone; Methylprednisolone Acetate; Omeprazole; Penicillins; Phenylcarbamates; Prednisone; Ranitidine; Recurrence; Sulfonamides; Syndrome; Terfenadine; Tosyl Compounds | 2002 |
Symptomatic and endoscopic outcome of heartburn 3-4.5 years after starting lansoprazole therapy: a prospective study of 142 patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Endoscopy, Gastrointestinal; Esophagitis; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Ranitidine; Treatment Outcome | 2003 |
Flavor and taste of lansoprazole strawberry-flavored delayed-release oral suspension preferred over ranitidine peppermint-flavored oral syrup: in children aged between 5-11 years.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Child; Child, Preschool; Consumer Behavior; Delayed-Action Preparations; Female; Flavoring Agents; Forecasting; Fragaria; Humans; Lansoprazole; Male; Mentha piperita; Omeprazole; Prospective Studies; Ranitidine; Suspensions; Taste | 2004 |
Mechanisms of action of leptin in preventing gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Lansoprazole; Leptin; Nitric Oxide; Omeprazole; Prostaglandin-Endoperoxide Synthases; Ranitidine; Rats; Rats, Wistar; Stomach Ulcer | 2005 |
Nasal pain disrupting sleep as a presenting symptom of extraesophageal acid reflux in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child, Preschool; Diet; Gastroesophageal Reflux; Histamine H2 Antagonists; Hoarseness; Humans; Lansoprazole; Life Style; Male; Nasal Cavity; Omeprazole; Pain; Proton Pump Inhibitors; Ranitidine; Sleep Initiation and Maintenance Disorders; Snoring | 2005 |
"Proton-pump inhibitor-first" strategy versus "step-up" strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cost-Benefit Analysis; Decision Support Techniques; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Japan; Lansoprazole; Models, Statistical; Omeprazole; Proton Pump Inhibitors; Ranitidine | 2005 |
[Cost-effectiveness analysis for the treatment of non-erosive reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Enzyme Inhibitors; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Proton Pump Inhibitors; Ranitidine | 2007 |
[The clinical effectiveness of rabeprazole in patients with acid-related gastric and duodenal diseases with various sensitivity of different types of parietal gastric cell receptors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Female; Gastric Acid; Gastric Acidity Determination; Gastritis; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Muscarinic Antagonists; Omeprazole; Parietal Cells, Gastric; Pirenzepine; Proton Pump Inhibitors; Rabeprazole; Ranitidine; Receptors, Histamine H2; Receptors, Muscarinic | 2007 |
Gastroprotective and antioxidant effects of montelukast on indomethacin-induced gastric ulcer in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetates; Animals; Anti-Ulcer Agents; Antioxidants; Catalase; Cyclopropanes; Dose-Response Relationship, Drug; Famotidine; Gastrointestinal Agents; Glutathione Reductase; Glutathione Transferase; Histamine H2 Antagonists; Indomethacin; Intubation, Gastrointestinal; Lansoprazole; Male; Molecular Structure; Peroxidase; Quinolines; Ranitidine; Rats; Rats, Sprague-Dawley; Stomach; Stomach Ulcer; Sulfides; Superoxide Dismutase | 2007 |
Pseudochromhidrosis: blue discolouration of the head and neck.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Bacillus; Facial Dermatoses; Gastrointestinal Agents; Humans; Lansoprazole; Malassezia; Male; Middle Aged; Pigments, Biological; Ranitidine; Scalp Dermatoses; Skin; Sweat Gland Diseases | 2007 |
Lansoprazole, ranitidine, and metoclopramide: comparison of practice patterns at 4 level III NICUs within one healthcare system.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Monitoring; Gastroesophageal Reflux; Guideline Adherence; Hospitals, Community; Hospitals, Teaching; Humans; Infant, Newborn; Intensive Care Units, Neonatal; Lansoprazole; Medical Records; Metoclopramide; Practice Patterns, Physicians'; Proton Pump Inhibitors; Ranitidine; Retrospective Studies; Utah | 2009 |
Novel approaches to inhibition of gastric acid secretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; Histamine Antagonists; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Ranitidine | 2010 |
Attenuation of stress-induced gastric lesions by lansoprazole, PD-136450 and ranitidine in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Animals; Indoles; Indomethacin; Injections, Subcutaneous; Lansoprazole; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Phenethylamines; Prostaglandin Antagonists; Proton Pump Inhibitors; Ranitidine; Rats; Rats, Wistar; Stomach Ulcer; Stress, Psychological | 2011 |
Effects of Morinda citrifolia aqueous fruit extract and its biomarker scopoletin on reflux esophagitis and gastric ulcer in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetic Acid; Animals; Biomarkers; Cisapride; Disease Models, Animal; Esophagitis, Peptic; Fruit; Gastric Acid; Gastric Mucosa; Gastrointestinal Agents; Gastrointestinal Transit; Lansoprazole; Male; Morinda; Pepsin A; Plant Extracts; Ranitidine; Rats; Rats, Wistar; Scopoletin; Serotonin; Stomach; Stomach Ulcer; Thailand | 2011 |
Time to stop blaming gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cough; Diagnosis, Differential; Electric Impedance; Enzyme Inhibitors; Esophageal pH Monitoring; Female; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Infant; Lansoprazole; Laryngopharyngeal Reflux; Logistic Models; Male; Pain; Ranitidine; Retrospective Studies | 2011 |
In vitro evaluation of phototoxic properties of proton pump inhibitors, H2-receptor antagonists and statins.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ascorbic Acid; Cimetidine; Erythrocytes; Famotidine; Hemolysis; Histamine H2 Antagonists; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lansoprazole; Lovastatin; Nizatidine; Omeprazole; Pantoprazole; Pravastatin; Proton Pump Inhibitors; Ranitidine; Ultraviolet Rays | 2012 |
Fluoroscopic balloon dilatation for caustic esophageal stricture in children: an 8-year experience.
Topics: Adolescent; Anesthesia, General; Anti-Ulcer Agents; Antibiotic Prophylaxis; Burns, Chemical; Caustics; Ceftriaxone; Child; Child, Preschool; Dilatation; Equipment Design; Esophageal Stenosis; Esophagoscopy; Female; Fluoroscopy; Gastroesophageal Reflux; Humans; Infant; Lansoprazole; Male; Radiography, Interventional; Ranitidine; Retrospective Studies; Treatment Outcome | 2013 |